Recovery is Achievable: Biocatalytic approaches to Diversifying Mitragynine Analogs for Opioid Substitution Therapies
康复是可以实现的:生物催化方法使帽柱木碱类似物多样化用于阿片类药物替代疗法
基本信息
- 批准号:10386083
- 负责人:
- 金额:$ 3.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAlkaloidsAmericanAnabolismAnalgesicsAttentionBindingBiochemicalBiochemistryClinical ResearchConstipationCyclizationDehydrationDependenceDevelopmentDisease ManagementEngineeringEnzyme TestsEnzymesExhibitsEyeGTP-Binding ProteinsGenerationsGenomeGoalsHomologous GeneHydroxylationIndole AlkaloidsLibrariesLifeMammalsMedicinal HerbsMedicinal PlantsMental DepressionMethadoneMethodsMethylationMiningMitragynaMolecularMonoterpenesMorphineNatural ProductsOpiate AddictionOpioidOpioid ReceptorOpioid RotationOpioid agonistOpioid replacement therapyOrganismPain managementPathway interactionsPatternPharmaceutical PreparationsPharmacologyPlant alkaloidPlantsProductionPropertyProtein EngineeringReactionRecoveryRelapseReportingResearchRouteSignaling ProteinSoutheastern AsiaStimulantStructureStructure-Activity RelationshipTherapeuticTreesUnited States Food and Drug AdministrationVentilatory Depressionaddictionanalogantagonistbasecatalystchronic pain managementdelta opioid receptordesigndrug discoveryenzyme pathwayexperiencefallsflexibilityfunctional groupimprovedmitragynine pseudoindoxylmu opioid receptorsnon-Nativenovelopioid epidemicopioid overdoseopioid use disorderopioid withdrawaloverdose deathpain reliefpandemic diseasereconstitutionresponsescaffoldside effectsmall moleculestereochemistrystrictosidine
项目摘要
Proposal Summary
Kratom (Mitragyna speciosa) is a medicinal plant that has been used in Southeast Asia for hundreds of years to
self-treat chronic-pain, opioid with-drawl, and depression. Due to these unique pharmacological effects, in the
past decade Kratom has flourished in the U.S. with many users self-treating opioid use disorder and pain
management. This medicinal herb has become a life-raft many use to pull themselves out of the pit of addiction,
rather than continuously falling in the trap of relapsing. Despite the recent attention, this plant remains
controversial in the eyes of the Food and Drug Administration and the Drug Enforcement Administration due to
limited or preliminary clinical research. Although, several studies have been conducted on Kratom’s primary
alkaloid mitragynine, characterizing it a partial antagonist of the μ-opioid receptor activated through the G-protein
signaling cascade. Kratom users report pain relieving properties and a depletion in negative side effects such as
constipation, addiction, and respiratory depression compared to morphine-based opioids. Furthermore, studies
show that some mitragynine analogs such as mitragynine pseudoindoxyl and 7-hydroxymitragynine are even
more potent agonists of the µ-opioid receptor, although a complete structure activity relationship of these
alkaloids has not been established. Thus, unanswered questions remain regarding where and how to manipulate
mitragynine to be the ultimate opioid substitution drug. Our goal is to fully elucidate the biosynthetic pathway of
mitragynine to determine the biocatalytic transformations required to produce the mitragynine scaffold.
Determining the biocatalytic pathway opens the door to manipulate critical catalysts that form mitragynine to
produce analogs that may enhance the pharmacological properties already displayed from this unique alkaloid.
Furthermore, we plan to derivatize mitragynine even further by characterizing and engineering flexible catalysts
from other organisms to produce mitragynine analogs with alternative cyclization, stereochemistry or functional
group patterns. Through this study we will generate a library of mitragynine analogs with the goal of identifying
effective candidates to help treat opioid use disorder. The overreaching hypothesis is that through methods of
protein engineering we can diversify the mitragynine scaffold beyond what is attainable through general synthetic
approaches and prepare novel compounds with enhanced pharmacological properties concerning opioid
response. Ultimately, mitragynine analogs have the potential to fast-track the development of new and safer
treatments for opioid use disorders therefore permanently improving the lives of those affected.
提案摘要
Kratom(Mitragyna speciosa)是一种药用植物,已在东南亚使用了数百年,
自我治疗慢性疼痛、阿片类药物和抑郁症。由于这些独特的药理作用,
过去十年Kratom在美国蓬勃发展.许多用户自我治疗阿片类药物使用障碍和疼痛
管理这种草药已经成为许多人用来把自己从上瘾的深渊中拉出来的救生筏,
而不是不断地落入复发的陷阱。尽管最近受到关注,但这种植物仍然
在食品和药物管理局和药品执法局的眼中,
有限或初步临床研究。虽然,几项研究已经进行了Kratom的主要
生物碱mitragynine,其特征是通过G蛋白激活的μ-阿片受体的部分拮抗剂
信号级联Kratom用户报告疼痛缓解属性和负面副作用,如消耗
与吗啡类阿片类药物相比,便秘、成瘾和呼吸抑制。此外,研究
显示了一些mitragynine类似物如mitragynine假吲哚和7-羟基mitragynine甚至
更有效的μ-阿片受体激动剂,尽管这些化合物的完整结构活性关系
生物碱尚未建立。因此,关于在何处以及如何操纵
mitragynine是最终的阿片类药物替代品。我们的目标是充分阐明的生物合成途径
用mitragynine测定产生mitragynine支架所需的生物催化转化。
确定生物催化途径打开了操纵形成mitragynine的关键催化剂的大门,
产生类似物,可以增强这种独特生物碱已经显示的药理学特性。
此外,我们计划通过表征和设计灵活的催化剂来进一步衍生Mitragynine
从其它生物体中分离得到具有交替环化、立体化学或功能性的mitragynine类似物,
群体模式通过这项研究,我们将产生一个图书馆的mitragynine类似物的目标是确定
有效的候选人,以帮助治疗阿片类药物使用障碍。过度假设是,通过
蛋白质工程,我们可以多样化的mitragynine支架超出了通过一般合成
方法和制备具有增强的关于阿片样物质的药理学性质的新化合物
反应最终,mitragynine类似物有可能快速开发新的和更安全的药物。
因此,对类阿片使用障碍的治疗永久地改善了受影响者的生活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalia Harris其他文献
Natalia Harris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalia Harris', 18)}}的其他基金
Recovery is Achievable: Biocatalytic approaches to Diversifying Mitragynine Analogs for Opioid Substitution Therapies
康复是可以实现的:生物催化方法使帽柱木碱类似物多样化用于阿片类药物替代疗法
- 批准号:
10557089 - 财政年份:2022
- 资助金额:
$ 3.89万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 3.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)